Form 4: Enanta CMO Sells Shares for Tax Obligations

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, sold 798 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Summary

• Chief Medical Officer Scott T. Rottinghaus sold 798 shares of Enanta Pharmaceuticals Inc. common stock.
• The transaction occurred on December 5, 2025.
• The shares were sold at a weighted-average price of $14.23, with individual transactions ranging from $13.89 to $14.46.
• The sale was non-discretionary, executed to cover tax withholding obligations arising from the settlement of a restricted stock unit award granted on November 23, 2022.
• Following this transaction, Rottinghaus beneficially owns 21,792 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to a restricted stock unit award, indicating a neutral impact on company sentiment as it is not a discretionary sale.

Positives

• The sale was explicitly stated as non-discretionary, solely to cover tax withholding obligations from a restricted stock unit award, rather than a voluntary divestment of shares based on a change in outlook.

Negatives

• An insider sold shares, which could be perceived negatively if the reason wasn't specified as non-discretionary.

Future Outlook

NA

Management Comments

• The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of shares, but its non-discretionary nature for tax purposes mitigates concerns about insider sentiment regarding the company's future.

Key Dates

Recommendation

The filing details a non-discretionary 'sell to cover' transaction by a Chief Medical Officer to satisfy tax obligations from a restricted stock unit award. This is a routine event and does not signal any change in the company's fundamental prospects or management's confidence. Therefore, it provides no new information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, insider transaction, stock sale, Chief Medical Officer, Scott T. Rottinghaus, restricted stock units, tax withholding